These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 9894728)

  • 1. Fulminant, CMV-associated, haemophagocytic syndrome following unrelated bone marrow transplantation.
    Sato M; Matsushima T; Takada S; Hatsumi N; Kim K; Sakuraya M; Saito T; Tamura J; Karasawa M; Murakami H; Naruse T
    Bone Marrow Transplant; 1998 Dec; 22(12):1219-22. PubMed ID: 9894728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new marrow T cell depletion method using anti-CD6 monoclonal antibody-conjugated magnetic beads and its clinical application for prevention of acute graft-vs.-host disease in allogeneic bone marrow transplantation: results of a phase I-II trial.
    Sao H; Kitaori K; Kasai M; Shimokawa T; Kato C; Yamanishi H; Ueda R; Morishima Y
    Int J Hematol; 1999 Jan; 69(1):27-35. PubMed ID: 10641440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.
    Herrera C; Torres A; García-Castellano JM; Roman J; Martin C; Serrano J; Falcon M; Alvarez MA; Gomez P; Martinez F
    Bone Marrow Transplant; 1999 Mar; 23(5):443-50. PubMed ID: 10100557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
    Hambach L; Eder M; Dammann E; Battmer K; Stucki A; Heil G; Ganser A; Hertenstein B
    Bone Marrow Transplant; 2001 Oct; 28(7):705-7. PubMed ID: 11704795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recovery from CMV esophagitis after allogeneic bone marrow transplantation using non-myeloablative conditioning: the role of immunosuppression.
    Fiegl M; Gerbitz A; Gaeta A; Campe H; Jaeger G; Kolb HJ
    J Clin Virol; 2005 Nov; 34(3):219-23. PubMed ID: 16129661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group.
    Takenaka K; Gondo H; Tanimoto K; Nagafuji K; Fujisaki T; Mizuno S; Miyamoto T; Okamura T; Hayashi S; Eto T; Osaki K; Yamasaki K; Shibuya T; Harada N; Teshima T; Matsuishi E; Minematsu T; Minamishima Y; Harada M; Niho Y
    Bone Marrow Transplant; 1997 Feb; 19(3):241-8. PubMed ID: 9028553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
    van Burik JA; Carter SL; Freifeld AG; High KP; Godder KT; Papanicolaou GA; Mendizabal AM; Wagner JE; Yanovich S; Kernan NA
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1487-98. PubMed ID: 18022579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CMV-viraemia during allogenic bone marrow transplantation in paediatric patients: association with survival and graft-versus-host disease.
    Matthes-Martin S; Aberle SW; Peters C; Holter W; Popow-Kraupp T; Pötschger U; Fritsch G; Ladenstein R; Rosenmayer A; Dieckmann K; Gadner H
    Bone Marrow Transplant; 1998 Apr; 21 Suppl 2():S53-6. PubMed ID: 9630327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
    Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
    Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [-Rejection of an allogeneic bone marrow graft following successful treatment of severe graft-versus-host disease (GVHD)].
    Sugimori N; Nakao S; Takamatsu H; Takami A; Ueda M; Shiobara S; Matsuda T
    Rinsho Ketsueki; 1996 Feb; 37(2):134-8. PubMed ID: 8852031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Requirements for early discharge after allogeneic bone marrow transplantation].
    Yasumi M; Karasuno T; Kanashima H; Masaie H; Taniguchi H; Mitsui H; Nakamura H; Hiraoka A
    Rinsho Ketsueki; 2001 Aug; 42(8):601-9. PubMed ID: 11579498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regimen-related mucosal injury of the gut increased the incidence of CMV disease after allogeneic bone marrow transplantation.
    Shigematsu A; Yasumoto A; Yamamoto S; Sugita J; Kondo T; Onozawa M; Kahata K; Endo T; Ota S; Sato N; Takahata M; Okada K; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):679-85. PubMed ID: 19450752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term remission of APL with a second allogeneic BMT after CNS relapse following HLA-identical allogeneic BMT.
    Classen CF; Debatin KM; Friedrich W; Schulz AS
    Bone Marrow Transplant; 2003 Oct; 32(8):843-6. PubMed ID: 14520432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe acute graft-versus-host disease occurring after syngeneic BMT for AML in a patient not given prior cyclosporin A therapy.
    Hwang WY; Goh YT; Tan CH; How GF; Tan HC
    Bone Marrow Transplant; 2000 Jan; 25(2):205-7. PubMed ID: 10673682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection.
    Avery RK; Bolwell BJ; Yen-Lieberman B; Lurain N; Waldman WJ; Longworth DL; Taege AJ; Mossad SB; Kohn D; Long JR; Curtis J; Kalaycio M; Pohlman B; Williams JW
    Bone Marrow Transplant; 2004 Dec; 34(12):1071-5. PubMed ID: 15489872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrotic syndrome as a clinical manifestation of graft-versus-host disease (GVHD) in a marrow transplant recipient after cyclosporine withdrawal.
    Oliveira JS; Bahia D; Franco M; Balda C; Stella S; Kerbauy J
    Bone Marrow Transplant; 1999 Jan; 23(1):99-101. PubMed ID: 10037059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive autologous graft-versus-host disease induced by cyclosporin A.
    Barredo JC; Yusuf U; Hahn A; Abboud MR; Laver J
    Bone Marrow Transplant; 1996 Sep; 18(3):659-62. PubMed ID: 8879637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
    Koga Y; Nagatoshi Y; Kawano Y; Okamura J
    Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Helper T-lymphocyte precursor frequency predicts the occurrence of graft-versus-host disease and disease relapse after allogeneic bone marrow transplantation from HLA-identical siblings.
    Leung AY; Kwok J; Lie AK; Chen P; Chen FE; Liang R
    Haematologica; 2001 Jun; 86(6):652-6. PubMed ID: 11418376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.